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nostic work-up of NSCLC patients’ leads to a reduction
of invasive procedures, resulting in cost savings of $669
per patient.
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THE COST OF GEMCITABINE/CISPLATIN
COMPARED WITH FOUR OTHER NOVEL
CHEMOTHERAPEUTIC AGENTS IN POLAND
Tilden DP1, Stynes G1, Aristides M1, Lis J2
1Medical Technology Assessment Group, Hammersmith,
United Kingdom; 2Eli Lilly Polska, Warsaw, Poland
OBJECTIVES: This study estimates the total health care
costs of ﬁve chemotherapeutic agents used to treat non-
small cell lung cancer (NSCLC) in Poland. This informa-
tion can be used to determine the most cost-efﬁcient
treatment option for health care providers in Poland.
METHODS: Two economic evaluations comparing 
gemcitabine/cisplatin (Gem/Cis) with four other novel
regimens were conducted using evidence from relevant
randomised controlled trials. The economic evaluation
based on the trial by Comella et al. (2000) compares
Gem/Cis with vinorelbine/cisplatin (Vin/Cis), while the
economic evaluation based on the trial by Schiller et al.
(2002) compares Gem/Cis with paclitaxel/cisplatin
(Pac/Cis), paclitaxel/carboplatin (Pac/Car), and doc-
etaxel/cisplatin (Doc/Cis). RESULTS: The economic eval-
uation based on the Comella et al. trial indicates that the
Gem/Cis combination is virtually cost neutral compared
to the Vin/Cis combination, costing an average of PLN
110 (€25) more per patient. The higher acquisition costs
of gemcitabine compared to vinorelbine were offset by
lower drug administration costs and lower rates of hos-
pitalisation for Gem/Cis patients. The economic evalua-
tion based on the Schiller et al. (2002) trial showed that
patients treated with Gem/Cis incurred higher total treat-
ment costs than those treated with Pac/Cis, by an average
of PLN 2880 (€652) per patient. However, patients
treated with Gem/Cis incurred signiﬁcantly lower total
treatment costs than those treated with Pac/Car and
Doc/Cis. The average cost savings associated with
Gem/Cis were PLN 1829 (€414) per patient and PLN
3921 (€888) per patient, respectively. CONCLUSIONS:
In Poland, Gem/Cis is the most advantageous treatment
alternative based on cost-minimisation for two out of 
the four comparators (Pac/Car and Doc/Cis). Using a
cost-effectiveness analysis, Gem/Cis is considered cost-
effective against the other two comparators (Vin/Cis 
and Pac/Cis). Overall, a claim for cost-effectiveness of
Gem/Cis regimens in the treatment of advanced NSCLC
is supported.
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OBJECTIVES: Complexed Prostate Speciﬁc Antigen
(cPSA) testing offers an improved speciﬁcity compared to
currently applied total PSA (tPSA) in the diagnosis of
prostate cancer in patients at risk. Our objective was to
assess the cost of cPSA if it would replace tPSA as ﬁrst
diagnostic test, based on medical management and cost
data for Belgium. Both tests have the same unit cost.
METHODS: A medical decision tree simulating a
patient’s ﬂow and applying a time horizon of one year
was developed in MS-Excel. Sensitivity and speciﬁcity
data were obtained from published directly comparative
clinical literature. An expert panel with 19 members (7
urologists and 12 general practioners) provided input
data regarding the further diagnostic work-up in case of
a positive PSA test and further therapeutical decisions and
medical resource use in relation to the diagnostic out-
comes (true and false positives and negatives). Costs of
medical resources were obtained from the public health
insurance perspective. RESULTS: When aiming for a
target sensitivity of 90%, a diagnosis starting with cPSA
costs €86.65 in total compared to €91.61 for tPSA. In a
second analysis, if published manufacturer cut-off values
were applied rather than a target sensitivity, total costs
were €75.50 and €91.60 respectively. The savings were
respectively €4.95 and €16.10 in favour of cPSA per
patient. For a yearly cohort of 500,000 men, savings up
to €8Mln could be realised. Sensitivity analyses on preva-
lence of prostate cancer and costs of diagnostic work-up
showed that the results were robust (savings range
€4.45–€5.46 in ﬁrst analysis and €13.3–€18.8 in second).
CONCLUSIONS: cPSA as standard screening test in
prostate cancer in patients at risk appears to have a strong
saving potential compared to the current use of tPSA.
Further research should focus on the psychological
impact of less false positive results.
CANCER—Quality of Life
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OBJECTIVE: To evaluate patient preference and Quality
of Life (QoL) with the administration of ﬁlgrastim versus
pegﬁlgrastim during myelosuppressive chemotherapy.
METHODS: Nine centres in France and 2 in Portugal
participated. The study was designed as an open-label,
cross-over trial with 76 cancer patients receiving 3 to 6
cycles of chemotherapy. Subjects were randomised on a 
1 :1 ratio to receive either multiple ﬁlgrastim injections
per cycle or pegﬁlgrastim as a single, ﬁxed-dose injection
once per cycle. In cycle 2, patients received the other study
medication. On day 1 of cycle 3, they were asked to com-
plete the Subject Preference Questionnaire to indicate
their preference for the remainder of the cycles. Data
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analysis was performed with the Mainland-Gart test and
the Fisher exact test. Subjects were also asked to ﬁll out
a generic QoL questionnaire (the Functional Assessment
of Cancer Therapy-General [FACT-G]) at the beginning
of each cycle and on day 14 with the Subject Outcome
Questionnaire (SOQ), which evaluates levels of pain, dis-
comfort, inconvenience, satisfaction, etc. RESULTS: Of
the 76 randomised patients, 74 took study medication, 4
discontinued, making a total of 70 evaluable subjects.
Overall, 58 patients preferred pegﬁlgrastim (83%; p <
0.001) after 2 cycles. Signiﬁcantly more patients preferred
pegﬁlgrastim when starting with ﬁlgrastim ﬁrst (94%
versus 73%, p < 0.001), indicating a clear sequential
effect. The main reason for the overall preference of peg-
ﬁlgrastim was dosing simpliﬁcation, safety and less pain.
Overall, mean SOQ scores were better in the pegﬁlgras-
tim arm (87.5% versus 78.9% in the ﬁlgrastim arm, p <
0.05). Differences in speciﬁc SOQ areas were predomi-
nantly found in the pegﬁlgrastim arm. FACT-G scores
showed no signiﬁcant differences between treatment arms
and cycles. CONCLUSION: Subjects demonstrated a
very strong preference for pegﬁlgrastim (83%), primarily
because of dosing simpliﬁcation. A higher proportion also
reported less pain, discomfort and inconvenience, as well
as greater treatment satisfaction.
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OBJECTIVES: Treatment Outcomes in Pain Survey
(TOPS) characterizes pain and health-related quality of
life (HRQL) with chronic nonmalignant pain (CNMP).
TOPS has 8 subscales from SF-36 Health Survey and 14
TOPS domains measuring physical, functional, and psy-
chosocial status. We evaluated TOPS in cancer-related
pain. METHODS: TOPS was administered to 150
patients with advanced cancer-related pain at three US
academic hospitals. Data were collected on demographic
variables, primary site of cancer, and cancer treatment
status. Pain was measured on a visual analogue scale.
Internal consistency reliability (Cronbach’s alpha) was
assessed for the 8 TOPS SF-36 subscales and 14 TOPS
domains. Cases were compared by treatment status, phys-
iologic sources of pain, and pain severity using Student-t
tests and the Mann-Whitney U tests. RESULTS: Physical,
functional, and psychosocial status differed by treatment
status. There were no signiﬁcant differences in TOPS SF-
36 and TOPS domains for subjects experiencing neuro-
pathic compared to non-neuropathic pain. However,
those with somatic pain reported greater Body Pain (p =
0.001) and Pain Symptoms (p < 0.05), and had worse
Total Pain Experience (p < 0.05). Greater pain was asso-
ciated with signiﬁcantly poorer outcomes on 5 of the 8
SF-36 subscales, with more Pain Symptoms (p < 0.001),
greater family disruptions (p < 0.001), poorer Passive
Coping (p < 0.05), and less Patient Satisfaction with Out-
comes (p < 0.01). Reliability for SF-36 subscales and
TOPS domains were all > 0.70, similar to prior TOPS
usage in CNMP. CONCLUSIONS: TOPS demonstr-
ated acceptable reliability with cancer-related pain and
detected signiﬁcant differences by treatment status, 
source of pain, and pain severity. That TOPS SF-36 and
TOPS domains differed by pain severity supports its
validity as a measure to assess pain outcomes and HRQL
in cancer. TOPS may also be a useful clinical tool to 
identify patients at risk for impaired physical function,
symptoms, emotional distress, disruptions in social rela-
tionships, and negative perceptions of satisfaction with
health care.
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OBJECTIVE: To examine the association between hemo-
globin levels and anemia diagnosis and to determine the
hemoglobin level that is most likely to trigger diagnosis
in oncology patients. METHODS: Members of a large US
health plan with an oncology diagnosis and chemo-
therapy claims between January 1, 2002 and February
28, 2002 were included in this retrospective claims data-
base analysis. Medical and laboratory claims were exam-
ined to identify chemotherapeutic episodes, International
Classiﬁcation of Diseases 9th Modiﬁcation (ICD-9) codes
for anemia, and hemoglobin values within each episode
and immediately preceding new anemia diagnoses.
Descriptive statistics and multivariate regression were
used to examine the relationship between anemia diag-
nosis and hemoglobin values. RESULTS: A total of 3180
chemotherapeutic episodes corresponding to 2717 oncol-
ogy patients were identiﬁed. In episodes in which the
hemoglobin dropped below 12g/dL (1689 episodes;
53%), an anemia diagnosis occurred in only 733 episodes
(45%). Additionally, an anemia diagnosis was found in
only 66% of the episodes where hemoglobin fell below
10.0g/dL. Being over 50 years old, having Non-Hodgkins
Lymphoma, and having fatigue or renal disease were
observed to increase the odds of diagnosis controlling for
hemoglobin nadir values and chemotherapeutic agent.
